Quote:The CDC doesn’t count every breakthrough case. It stopped counting all breakthrough cases May 1 and now only tallies those that lead to hospitalization or death, a move the agency was criticized for by health experts.

Quote:Inseego price target raised to $17 from $13 at Lake Street 09:16 INSG Lake Street analyst Jaeson Schmidt raised the firm's price target on Inseego to $17 from $13 and keeps a Buy rating on the shares. While he thinks the biggest surprise for investors from the company's quarterly report will be the lack of guidance, Schmidt argues that the lack of guidance should not overshadow the company's bullish commentary and continued IoT and mobile momentum. He also does not think investors should forget about the significant opportunity in 5G, which he says "was always set to be a 2H20 story."

Quote:Inseego downgraded to Neutral on valuation at Roth Capital 09:01 INSG As previously reported, Roth Capital analyst Scott Searle downgraded Inseego to Neutral from Buy on valuation, with a price target of $10.50, down from $13.25. The analyst notes that while Inseego reported 44% sales growth, results fell short of mobile hotspot expectations. Additionally, higher costs translated to lower gross margins and EBITDA, he adds, However, Searle acknowledges that overall 5G hotspot and FWA activity remains robust with 8 5G products across 6 carriers expected to ship by year end.

Quote:The company has simplified the testing of PAD, which is a marker for increased risk of stroke and cardiovascular disease. It runs on a capital light, license fee business model that generates high margins and substantial cash flows. The pandemic has interrupted the progress, but the company seems well placed to weather the storm.